TRANSGENIC MICE EXPRESSING HIGH-LEVELS OF SOLUBLE TNF-R1 FUSION PROTEIN ARE PROTECTED FROM LETHAL SEPTIC SHOCK AND CEREBRAL MALARIA, AND ARE HIGHLY SENSITIVE TO LISTERIA-MONOCYTOGENES AND LEISHMANIA-MAJOR INFECTIONS

被引:122
作者
GARCIA, I
MIYAZAKI, Y
ARAKI, K
ARAKI, M
LUCAS, R
GRAU, GE
MILON, G
BELKAID, Y
MONTIXI, C
LESSLAUER, W
VASSALLI, P
机构
[1] INST PASTEUR,UNITE IMMUNOL CELLULAIRE,PARIS,FRANCE
[2] F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES,CH-4002 BASEL,SWITZERLAND
关键词
TUMOR NECROSIS FACTOR RECEPTOR 1 FUSION PROTEIN; TRANSGENIC MICE; SEPTIC SHOCK; LISTERIA MONOCYTOGENES; LEISHMANIA MAJOR;
D O I
10.1002/eji.1830250841
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Mice bearing a transgene coding for a soluble tumor necrosis factor receptor type 1 (TNFR1)-FcIgG3 fusion protein and placed under the control of the alpha-l-antitrypsin gene promoter were generated. Depending on the mouse line, blood levels of the protein ranged from 25 ng/ml to over 100 mu g/ml; this level of expression was most often transmitted to the transgene-bearing progeny as a relatively stable feature. High-expressor mice were completely resistant to lipopolysaccharide-induced shock and lethality, including after D-galactosamine sensitization, and mice expressing about 1 mu g of the fusion protein/ml were partially (60 %) protected. In contrast, mice expressing less than 0.1 mu g of the protein/ml were more sensitive than controls with respect to incidence and time of death, even though the biological activity of serum tumor necrosis factor (TNF) was partially neutralized. High-expressor mice of the adequate genetic background were markedly although not completely protected from death by cerebral malaria after injection with Plasmodium berghei. They were highly susceptible to Listeria monocytogenes, dying from bacterial dissemination after sublethal infection, and to Leishmania major; displaying severe, non-healing lesions after local infection. Under the same conditions, mice expressing about 1 mu g protein/ml were only partially sensitive to these last agents, compared to non-transgenic littermate mice which were fully resistant. These transgenic mice represent a model of permanent, complete or partial, impairment of TNF use, which compares favorably, for ease of breeding and for the range of effects, to mice bearing gene disruptions.
引用
收藏
页码:2401 / 2407
页数:7
相关论文
共 30 条
[1]   STABILIZATION OF THE BIOACTIVITY OF TUMOR-NECROSIS-FACTOR BY ITS SOLUBLE RECEPTORS [J].
ADERKA, D ;
ENGELMANN, H ;
MAOR, Y ;
BRAKEBUSCH, C ;
WALLACH, D .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (02) :323-329
[2]   NEONATAL HEPATITIS INDUCED BY ALPHA-1-ANTITRYPSIN - A TRANSGENIC MOUSE MODEL [J].
DYCAICO, MJ ;
GRANT, SGN ;
FELTS, K ;
NICHOLS, WS ;
GELLER, SA ;
HAGER, JH ;
POLLARD, AJ ;
KOHLER, SW ;
SHORT, HP ;
JIRIK, FR ;
HANAHAN, D ;
SORGE, JA .
SCIENCE, 1988, 242 (4884) :1409-1412
[3]   DECREASED SENSITIVITY TO TUMOR-NECROSIS-FACTOR BUT NORMAL T-CELL DEVELOPMENT IN TNF RECEPTOR-2-DEFICIENT MICE [J].
ERICKSON, SL ;
DESAUVAGE, FJ ;
KIKLY, K ;
CARVERMOORE, K ;
PITTSMEEK, S ;
GILLETT, N ;
SHEEHAN, KCF ;
SCHREIBER, RD ;
GOEDDEL, DV ;
MOORE, MW .
NATURE, 1994, 372 (6506) :560-563
[4]   PROTECTIVE EFFECT OF 55-KD BUT NOT 75-KD SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTOR IMMUNOGLOBULIN-G FUSION PROTEINS IN AN ANIMAL-MODEL OF GRAM-NEGATIVE SEPSIS [J].
EVANS, TJ ;
MOYES, D ;
CARPENTER, A ;
MARTIN, R ;
LOETSCHER, H ;
LESSLAUER, W ;
COHEN, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (06) :2173-2179
[5]   COMPARISON OF INVITRO-CELL CYTO-TOXIC ASSAYS FOR TUMOR NECROSIS FACTOR [J].
FLICK, DA ;
GIFFORD, GE .
JOURNAL OF IMMUNOLOGICAL METHODS, 1984, 68 (1-2) :167-175
[6]  
GIRARDIN E, 1992, IMMUNOLOGY, V76, P20
[7]   TUMOR-NECROSIS-FACTOR (CACHECTIN) AS AN ESSENTIAL MEDIATOR IN MURINE CEREBRAL MALARIA [J].
GRAU, GE ;
FAJARDO, LF ;
PIGUET, PF ;
ALLET, B ;
LAMBERT, PH ;
VASSALLI, P .
SCIENCE, 1987, 237 (4819) :1210-1212
[8]  
HAVELL EA, 1989, J IMMUNOL, V143, P2894
[9]   CYTOKINE-BINDING PROTEINS - STIMULATING ANTAGONISTS [J].
KLEIN, B ;
BRAILLY, H .
IMMUNOLOGY TODAY, 1995, 16 (05) :216-220
[10]  
Kossodo S., 1992, J EXP MED, V176, P1259